"Schweitzer and Lu's new edition provides a broad and timely overview of pharmaceutical economics and policy issues. Topics of particular current interest include biotechnology and biosimilars, international differences in drug prices and regulations, and the contricutuion and affordability of new medical advances."-Henry G. Grabowski, Professor Emeritus of Economics, Duke University
" a must have if you are seriously interested in the domestic and international pharmaceutical industry." -Journal of Public Health Policy
"This book is easy to read and provides an excellent overview of the pharmaceutical industry This book makes a useful contribution to anyone interested in understanding pharmaeconomic theory and the characteristics of the pharmaceutical industry." -Inquiry
Review
"Schweitzer and Lu's new edition provides a broad and timely overview of pharmaceutical economics and policy issues. Topics of particular current interest include biotechnology and biosimilars, international differences in drug prices and regulations, and the contricutuion and affordability of new medical advances."-Henry G. Grabowski, Professor Emeritus of Economics, Duke University
" a must have if you are seriously interested in the domestic and international pharmaceutical industry." -Journal of Public Health Policy
"This book is easy to read and provides an excellent overview of the pharmaceutical industry This book makes a useful contribution to anyone interested in understanding pharmaeconomic theory and the characteristics of the pharmaceutical industry." -Inquiry
Book Description
Provides comprehensive discussions on a wide range of pharmaceutical economics and policy issues.
From the Publisher
Stuart O. Schweitzer is Professor of Health Policy and Management at UCLA's Fielding School of Public Health. He has held other academic and research appointments at the Urban Institute and the White House Commission for a National Agenda for the Eighties. His research and consulting activities have dealt with pharmaceutical regulation and policy, health care financing, and technology assessment.
Z. John Lu is Assistant Professor of Economics at the MVS School of Business and Economics, California State University, Channel Islands. Prior to this academic position, Dr. Lu was a health economist in the biopharmaceutical industry for 2 decades, including nearly 17 years at Amgen, where he was a director of global health economics and policy. Professor Lu's research interests include industrial economics and policy on pharmaceuticals, particularly in the United States and China.
About the Author
Stuart O. Schweitzer is Professor of Health Policy and Management at UCLA's Fielding School of Public Health. He has held other academic and research appointments at the Urban Institute and the White House Commission for a National Agenda for the Eighties. His research and consulting activities have dealt with pharmaceutical regulation and policy, health care financing, and technology assessment.
Z. John Lu is Assistant Professor of Economics at the MVS School of Business and Economics, California State University, Channel Islands. Prior to this academic position, Dr. Lu was a health economist in the biopharmaceutical industry for 2 decades, including nearly 17 years at Amgen, where he was a director of global health economics and policy. Professor Lu's research interests include industrial economics and policy on pharmaceuticals, particularly in the United States and China.